Europe Prosthetic Heart Valve Market Size, Share, Competitive Landscape and Trend Analysis Report, by Product, : Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics 

Europe prosthetic heart valve market growth driven by technological advancements and increasing awareness of cardiovascular health. The aging population in Europe, coupled with rising incidences of heart valve diseases, has created a substantial demand for prosthetic heart valves. As life expectancy increases, so does the prevalence of degenerative heart valve conditions, necessitating more frequent valve replacements. In addition, technological innovations led to the development of minimally invasive procedures and transcatheter heart valve implantations, which offer reduced recovery times and improved outcomes for patients thereby supporting the market growth.

Further,  Europe prosthetic heart valve market trends include the growing adoption of tissue-engineered heart valves and the continuous refinement of mechanical valves have enhanced the durability and performance of prosthetic options. Increased healthcare expenditure in many European countries, along with improved reimbursement policies for heart valve procedures, has made these treatments more accessible to a broader population. The rise in healthcare infrastructure and the presence of skilled cardiac surgeons and interventional cardiologists across Europe have also facilitated Europe prosthetic heart valve market growth.

However, the high costs associated with prosthetic heart valve procedures and devices pose a significant barrier, limiting access for many patients and straining healthcare systems. In addition, the risk of complications such as thromboembolism, endocarditis, and structural valve deterioration remains a concern, necessitating long-term anticoagulation therapy for some patients and impacting quality of life thereby restricts the market growth. On the other hand, ongoing R&D activities efforts in tissue engineering and novel biomaterials could lead to more durable and biocompatible valve options provides growth during the Europe prosthetic heart valve market forecast period.  

Market Segmentation

The Europe prosthetic heart valve market size is segmented on the basis of product and country. On the basis of product, the market is categorized into mechanical heart valve, tissue heart valve, and transcatheter heart valve. The tissue heart valve segment is further classified into stented tissue heart valve and stent less tissue heart valve. The transcatheter heart valve segment dominated the Europe prosthetic heart valve market share in 2023, owing to patients increasingly prefer less invasive treatment options with reduced hospital stays and faster recovery, which aligns with the benefits offered by transcatheter heart valves. On the basis of country the market is classified into Germany, France, UK, Italy, Spain, and Rest of Europe.

Industry Trends

• The UK government has launched the £30 million Health Technology Adoption and Acceleration Fund (HTAAF) in October 2023 to enable integrated care systems (ICSs) to invest in medtech to support winter pressures. In addition, the National Institute for Health and Care Excellence (NICE) will undertake 8 late-stage assessments (LSAs) during 2023 to 2024 and 2024 to 2025, with the first LSA launched in October 2023 reviewing transcatheter aortic valve implantations. These initiatives collectively support the advancement and increased adoption of prosthetic heart valves in the UK healthcare system.
• In May 2023, MedTech Europe launched a campaign to prioritize cardiovascular health at the EU level, highlighting the need for a coordinated policy approach to tackle cardiovascular diseases, which are the leading cause of death in the region. The campaign emphasizes the importance of early diagnosis and efficient management of heart conditions, including valve diseases,  to alleviate the burden on healthcare systems.

Competitive Landscape 

The key players operating in the Europe prosthetic heart valve industry are Bracco, Edwards Lifesciences Corporation, Medtronic, Boston Scientific Corporation, Abbott Laboratories, Artivion, Inc, Meril Life Sciences Pvt. Ltd., ShockWave Medical, Inc., Novostia SA, and JenaValve Technology, Inc. These players have adopted various developmental strategies to stay competitive in the market. For instance, in May 2024, Edwards Lifesciences announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed to extend the valve’s durability.

Key Benefits for Stakeholders

• The report provides a comprehensive analysis of the current market estimations through 2024-2033, which would enable the stakeholders to capitalize on prevailing market opportunities.
• Major countries are mapped according to their revenue contribution to the Europe prosthetic heart valve market.
• In-depth analysis of the Europe prosthetic heart valve market segmentation assists to determine the prevailing market opportunities.
• Identify key players and their strategic moves in Europe prosthetic heart valve industry.
• Assess and rank the top factors that are expected to affect the growth of Europe prosthetic heart valve market.
• Analyze the market factors in various countries and understand business opportunities.
• Player positioning provides a clear understanding of the present position of key market players.